1. Home
  2. KOPN vs MDXH Comparison

KOPN vs MDXH Comparison

Compare KOPN & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kopin Corporation

KOPN

Kopin Corporation

HOLD

Current Price

$2.40

Market Cap

424.9M

Sector

Technology

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.20

Market Cap

167.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOPN
MDXH
Founded
1984
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
424.9M
167.8M
IPO Year
1992
2021

Fundamental Metrics

Financial Performance
Metric
KOPN
MDXH
Price
$2.40
$3.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$4.25
$7.67
AVG Volume (30 Days)
3.3M
124.2K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$45,602,295.00
$103,069,000.00
Revenue This Year
N/A
$23.34
Revenue Next Year
$43.33
$22.98
P/E Ratio
N/A
N/A
Revenue Growth
3.02
21.68
52 Week Low
$0.71
$1.35
52 Week High
$4.16
$5.33

Technical Indicators

Market Signals
Indicator
KOPN
MDXH
Relative Strength Index (RSI) 42.73 31.91
Support Level $2.28 $3.10
Resistance Level $2.65 $3.40
Average True Range (ATR) 0.20 0.16
MACD -0.00 -0.01
Stochastic Oscillator 22.22 7.81

Price Performance

Historical Comparison
KOPN
MDXH

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: